Standardizing EBOO Experiments: A Methodological Guide to Priming, Sampling, and Ensuring Reproducibility

A practical step-by-step protocol for lab managers and research associates: blood handling, circuit priming, parameter control, sampling strategy, and…

For research and institutional laboratory use only. The EBOO O3 Research Device 2026 is not cleared or approved by the U.S. FDA for clinical, diagnostic, or therapeutic applications. The procedures described below are general methodological recommendations for ex vivo extracorporeal circuit research — they do not constitute validated standard operating procedures for any specific regulatory application.

Introduction: The Reproducibility Challenge in Extracorporeal Research

Extracorporeal circulation experiments introduce a level of methodological complexity that bench-top assays do not. When blood leaves a collection vessel, enters a closed-loop circuit, passes through an ozone generator and a membrane filter, and returns — dozens of variables are in play simultaneously. Temperature drift, air entrainment, inconsistent priming, sampling timing errors, and anticoagulant choice can each independently shift experimental outcomes beyond the bounds of meaningful comparison.

The result is a reproducibility problem. Two laboratories using identical EBOO hardware, identical ozone concentrations, and identical blood volumes can produce divergent biomarker profiles if their EBOO experiment protocol differs in seemingly minor procedural details. A 2-minute delay in sample processing, a partially primed filter, or a different anticoagulant concentration can introduce systematic bias that is invisible in a single dataset but becomes obvious when results fail to replicate.

This guide addresses that problem directly. It provides a structured, step-by-step methodology for setting up, running, and validating EBOO experiments — with emphasis on the procedural details that most affect reproducibility extracorporeal research. The goal is not to prescribe a single protocol for all applications, but to identify the critical control points where standardization has the greatest impact on data quality.

Pre-Experimental Setup

Blood Handling and Anticoagulation

The quality of an EBOO experiment is determined before the circuit is turned on. Blood handling procedure begins at the point of collection and extends through every step until the sample enters the circuit.

Anticoagulant Selection

The choice of anticoagulant has downstream consequences that must be understood and documented:

Sodium Citrate (3.2% or 3.8%) — Chelates calcium ions, reversibly inhibiting the coagulation cascade. Preferred when coagulation parameters (PT, aPTT, fibrinogen) are part of the biomarker panel, because anticoagulation can be reversed by recalcification testing (adding CaCl2 to restore physiological calcium levels). Citrate is also preferred for platelet function studies because it minimally activates platelets during collection.

Sodium Heparin (10-20 IU/mL) — Activates antithrombin III, inhibiting thrombin and Factor Xa. Provides robust anticoagulation suitable for longer circuit runs (>60 minutes). However, heparin can activate complement and interfere with certain immunoassays. Not suitable for coagulation endpoint studies.

EDTA (K2EDTA or K3EDTA) — Strong calcium chelator. Excellent for complete blood count (CBC) preservation but causes irreversible platelet shape change and is incompatible with most coagulation and calcium-dependent assays. Generally avoided for EBOO circuit work except for specific hematology endpoints.

Recommendation: For most EBOO experiments, sodium citrate (3.2%) provides the best balance of anticoagulation efficacy, assay compatibility, and reversibility via recalcification testing. Document the exact citrate concentration and blood-to-anticoagulant ratio (typically 9:1) in all protocol records.

Temperature Control

Maintain collected blood at 20-24 degrees C (room temperature) if the experiment begins within 30 minutes of collection.
If a delay exceeds 30 minutes, store at 4 degrees C and allow a 15-minute equilibration to room temperature before circuit introduction.
Never freeze whole blood intended for circuit experiments — freeze-thaw cycles cause hemolysis and alter rheological properties.
Record the temperature of the blood at the point of circuit introduction. A 5 degree C difference in starting temperature can measurably affect viscosity and ozone solubility.

Pre-Circuit Quality Check

Before introducing blood into the EBOO circuit, perform a baseline quality assessment:

Visual inspection for hemolysis (pink or red discoloration of plasma after gentle centrifugation of a 1 mL aliquot)
Baseline CBC to establish starting cell counts
Baseline free plasma hemoglobin (fHb) to quantify pre-existing hemolysis
Record the time elapsed since collection

Circuit Priming: Eliminating Air and Establishing Consistent Flow

Priming EBOO circuit correctly is arguably the single most important procedural step for reproducibility. Residual air in the circuit causes microbubble formation, inconsistent flow, and localized areas of stasis where blood components can aggregate on membrane surfaces.

Step-by-Step Priming Protocol

Assemble the circuit — Connect the Filters and Lines Complete Kit to the EBOO O3 Research Device 2026 following the manufacturer's assembly diagram. Ensure all luer connections are finger-tight with a quarter-turn past initial resistance. Do not over-tighten.

Prepare the priming solution — Use isotonic saline (0.9% NaCl) at room temperature. Volume required: approximately 150-200 mL (sufficient to fill the entire circuit volume including filter, tubing lines, and drip chambers).

Prime the arterial line — With the pump off, gravity-feed saline from an elevated IV bag through the arterial (inlet) line. Allow saline to fill the line completely, watching for air bubbles. Tap the line gently to dislodge any adherent bubbles.

Prime the filter — Once saline reaches the filter housing, orient the filter vertically with the outlet port uppermost. Allow saline to fill the filter from bottom to top, displacing air upward through the outlet port. This orientation is critical — horizontal priming traps air in the fiber bundle.

Prime the venous line — Continue gravity flow through the venous (outlet) line until saline exits the distal end. Clamp the venous line.

Recirculate priming solution — Start the peristaltic pump at the minimum flow rate (approximately 50 mL/min). Recirculate saline through the closed circuit for 2-3 minutes, observing for residual air bubbles in the drip chambers and tubing.

Final air check — Stop the pump. Visually inspect the entire circuit — filter housing, drip chambers, all tubing segments, and connectors — for any visible air. If air is present, resume recirculation at low flow until cleared.

Drain priming solution — Open the venous line clamp and drain saline into a waste container. The circuit is now primed and ready for blood introduction.

Critical Note: Do not allow the primed circuit to sit idle for more than 10 minutes before blood introduction. Prolonged contact between saline and the PES membrane can alter wetting characteristics and affect initial flow resistance.

Running the Experiment

Parameter Control and Monitoring

Once blood enters the primed circuit, the experiment begins. The following parameters must be set, monitored, and recorded at defined intervals:

Flow Rate

Set the target flow rate on the EBOO O3 Research Device 2026 digital control panel (range: 2.5-5 L/hr, equivalent to approximately 42-83 mL/min).
Allow 60-90 seconds for flow to stabilize after pump initiation.
Record actual flow rate at T=0, T=5 min, and every 15 minutes thereafter. Flow rate drift >10% from target indicates a developing obstruction (clot formation, filter fouling) and should trigger protocol review.

Ozone Concentration

Set the target ozone concentration using the device's adjustable gamma control (range: 1-35 gamma).
Allow a 30-second stabilization period after ozone initiation before recording the baseline ozone reading.
Document the gamma setting, not just the intended concentration — this ensures traceability to the device's calibration state.

Circuit Temperature

Monitor the temperature at the circuit outlet using the device's integrated sensors or an inline thermocouple.
Temperature should remain within plus or minus 2 degrees C of the starting value throughout the run. Significant drift indicates either environmental exposure or excessive pump-induced heating.

Recirculation Volume and Pass Count

For recirculation experiments, calculate and record the number of complete passes: Total passes = (Flow rate x Run time) / Circuit volume.
Example: At 3 L/hr with a 200 mL circuit volume and a 60-minute run, the blood completes approximately 15 passes through the ozone chamber and filter.

Sampling Protocol

Inconsistent sampling is the most common source of unexplained variability in extracorporeal research. Standardize every aspect of sample collection:

Sampling Port Location

Collect all timed samples from the same port — typically a three-way stopcock on the venous (post-filter) line.
If both pre-filter and post-filter samples are needed (e.g., for single-pass extraction studies), install dedicated sampling ports on both the arterial and venous lines during circuit assembly.

Sampling Schedule

A recommended sampling timeline for a 60-minute recirculation experiment:

T=0 (Baseline) — Immediately after blood enters the circuit and before ozone initiation. This is the true baseline — not the pre-circuit blood sample, which has not been exposed to the circuit surfaces.
T=5 min — Early response sample. Captures acute phase reactions to ozone and circuit contact.
T=15 min — First intermediate sample.
T=30 min — Midpoint sample.
T=45 min — Second intermediate sample.
T=60 min (End) — Final sample before pump shutdown.

Sample Volume and Processing

Draw 2-5 mL per time point, depending on the biomarker panel. Account for cumulative volume loss — removing 5 mL x 6 time points = 30 mL from a 500 mL circuit reduces total volume by 6%, which may affect flow dynamics in late samples.
Immediately aliquot samples into pre-labeled tubes appropriate for each assay (e.g., EDTA for CBC, citrate for coagulation, plain tube for serum).
Process within 30 minutes of collection: centrifuge plasma/serum samples at 1500-2000 x g for 10 minutes at 4 degrees C.
Snap-freeze aliquots in liquid nitrogen or a -80 degrees C freezer within 60 minutes of collection.
Record the exact time of each sample collection (to the minute) — not just the target time point.

Post-Experimental Analysis and Validation

Circuit Rinse and Recovery

After the final sample is collected and the pump is stopped:

Saline rinse — Disconnect the blood reservoir and connect a 250 mL bag of isotonic saline. Run the pump at the experimental flow rate for 3 minutes to flush residual blood from the circuit. Collect the rinse effluent separately — it contains blood components that were in transit and may be analyzed for dilution-corrected endpoint values.

Filter recovery (optional) — For studies investigating membrane-adherent components (adsorbed proteins, trapped cells, fibrin deposition), carefully disassemble the filter housing. The filter membrane can be processed for histological staining, electron microscopy, or protein elution using appropriate buffers.

Tubing inspection — Visually inspect all tubing segments for clot formation, discoloration, or material degradation. Document findings photographically. Any visible clot indicates a potential coagulation event during the run that may have affected downstream biomarker results.

Quality Control Checks

Before analyzing experimental endpoints, perform these validation checks to confirm data integrity:

Hemolysis Assessment

Compare baseline (T=0) and final (T=60) free plasma hemoglobin (fHb) values.
An increase in fHb >50 mg/dL suggests significant hemolysis during the circuit run, which may confound oxidative stress and inflammatory marker results.
If hemolysis exceeds your predefined threshold, flag the run for sensitivity analysis or exclusion.

Cell Count Recovery

Compare baseline and final CBC values (corrected for dilution from any saline additions).
A decrease in white blood cell count >15% may indicate leukocyte adhesion to the circuit or filter.
A decrease in platelet count >20% may indicate platelet activation and aggregation within the circuit.

Flow Rate Consistency

Review the flow rate log. Runs where flow rate deviated >10% from target for more than 5 consecutive minutes should be flagged.
Calculate the coefficient of variation (CV) for flow rate across all recorded time points. Target CV <5%.

Troubleshooting Common Methodological Issues

Foaming in the Drip Chamber

Cause: Excessive ozone flow relative to blood flow, or protein denaturation at the gas-liquid interface. Solution: Reduce ozone gamma setting by 20%, verify flow rate is within target range, ensure the drip chamber is at least half-filled with blood to reduce the gas-liquid surface area.

Progressive Flow Rate Decline

Cause: Filter fouling from fibrin deposition, platelet aggregation, or inadequate anticoagulation. Solution: Verify anticoagulant concentration is correct for the expected run duration. Consider adding a supplemental heparin bolus (2-5 IU/mL) to the circuit for runs exceeding 45 minutes with citrated blood. Check that the priming protocol was completed fully — residual air in the filter accelerates fouling.

Inconsistent Ozone Delivery

Cause: Moisture in the ozone generator feed gas, or a depleted oxygen source. Solution: Verify the oxygen supply pressure and purity (medical-grade at least 93%). Check the ozone generator desiccant or moisture trap if applicable. Allow a 60-second warm-up period before recording ozone output.

Clot Formation in Tubing

Cause: Insufficient anticoagulation, stagnant zones in the circuit (kinked tubing, partially closed stopcocks), or excessive run duration. Solution: Inspect circuit geometry for kinks or restrictions before each run. Ensure all stopcocks are fully open in the flow direction. For runs >60 minutes, consider continuous heparin infusion via a syringe pump into the arterial line.

Sample Hemolysis at Collection

Cause: Drawing samples too rapidly through a small-bore stopcock, creating shear-induced hemolysis at the sampling point rather than in the circuit. Solution: Use a slow, steady draw technique. Allow 10-15 seconds per mL of sample. Use a larger-bore sampling port if available.

Conclusion: Reproducible Research Starts With a Defined Protocol

The difference between an experiment and a demonstration is documentation and control. Every step outlined in this guide — from anticoagulant selection to sampling port location to post-run hemolysis assessment — represents a variable that, if left uncontrolled, becomes a source of noise in your data.

The EBOO O3 Research Device 2026 provides the hardware foundation for parametric control: digital flow adjustment (2.5-5 L/hr), adjustable ozone output (1-35 gamma), integrated safety monitoring, and standardized circuit connections. Matched Filters and Lines Complete Kits ensure that the disposable circuit components are consistent from run to run and from lab to lab — eliminating a major source of inter-laboratory variability.

But hardware consistency is only half the equation. Protocol consistency — the human decisions documented in this guide — is the other half. We encourage research teams to adapt this framework to their specific experimental objectives, document every deviation, and share their refined protocols with the broader research community.

For detailed product manuals, specification sheets, or protocol consultation, contact the EBOO Filters research support team.

For research and institutional laboratory use only. Not cleared or approved by the U.S. FDA for clinical, diagnostic, or therapeutic applications. No claims of efficacy for any diagnostic or therapeutic purpose are made or implied.